AI Matters
Why it matters
OpenAI buys Orchestra Bio to expand its drug development tools
The Decoder OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with Rosalind, its life sciences AI platform, to build agents that help coordinate drug development.
Why it matters
Signals AI companies are moving into medicine, which could eventually speed up how new drugs are tested and brought to patients.
Latest brief · Oct 21, 2026